Several analysts have recently updated their ratings and price targets for Myriad Genetics (NASDAQ: MYGN):
- 11/12/2026 – Myriad Genetics had its price target raised by Stephens from $3.00 to $6.00. They now have an “equal weight” rating on the stock.
- 11/12/2026 – Myriad Genetics had its price target raised by Stephens from $3.00 to $6.00. They now have an “equal weight” rating on the stock.
- 11/7/2026 – Myriad Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
- 11/5/2026 – Myriad Genetics had its price target raised by TD Cowen from $4.50 to $6.75. They now have a “hold” rating on the stock.
- 11/5/2026 – Myriad Genetics had its price target raised by Leerink Partners from $5.00 to $8.00. They now have a “market perform” rating on the stock.
- 10/27/2026 – Myriad Genetics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 10/20/2026 – Myriad Genetics was given a new $4.50 price target by Wells Fargo & Company.
- 10/20/2026 – Myriad Genetics was upgraded by Piper Sandler from “underweight” to “neutral”. They now have a $5.00 price target on the stock.
- 10/15/2026 – Myriad Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
- 10/13/2026 – Myriad Genetics had its price target raised by TD Cowen from $4.00 to $4.50. They now have a “hold” rating on the stock.
- 10/12/2026 – Myriad Genetics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 10/2/2026 – Myriad Genetics had its price target raised by Craig Hallum from $4.00 to $8.00. They now have a “buy” rating on the stock.
Myriad Genetics Stock Performance
NASDAQ:MYGN opened at $5.66 on Monday. The company has a quick ratio of 1.77, a current ratio of 1.98 and a debt-to-equity ratio of 0.45. Myriad Genetics, Inc. has a twelve month low of $2.74 and a twelve month high of $8.09. The company has a fifty day moving average of $4.75 and a 200-day moving average of $4.62. The firm has a market capitalization of $542.91 million, a P/E ratio of -4.16 and a beta of 1.62.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 19.87% and a negative net margin of 16.07%. The company had revenue of $202.70 million for the quarter, compared to analyst estimates of $191.33 million. As a group, sell-side analysts anticipate that Myriad Genetics, Inc. will post -1.02 EPS for the current year.
Read More
- Five stocks we like better than Myriad Genetics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
